News

Alnylam and Cubist have provided complete data from their phase II study of ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection. The phase

Idenix has completed a three-day proof-of-concept study of IDX184. The company is developing IDX184, a novel liver-targeted prodrug of 2′-methyl guanosine nucleotide, for the treatment of Hepatitis C

Mylan Pharmaceuticals has received approval from the FDA for its supplemental Abbreviated New Drug Application (ANDA) for Haloperidol Tablets USP, 10mg and 20mg. These strengths are in addition

The Dutch Medicines Evaluation Board (MEB) has informed Eurand that the Decentralized Procedure (DCP) for registration of Paracetamol 250 and 500mg Orodispersible Tablets (ODT) in several EU countries,

Ardea Biosciences has initiated phase 2b clinical trial of RDEA594 for the management of hyperuricemia and gout. Reportedly, the randomized, double-blind, placebo-controlled, dose-response study will evaluate the safety

For the three months ended 2009, Elan has reported total revenues of $280.9m, compared to $245.6m for the same period, 2008. The operating loss of the company has

CytRx has announced that treatment with its cancer drug candidate INNO-206 resulted in a statistically significant reduction in the average primary tumor size in an animal model of

ImClone and Bristol-Myers Squibb has announced that the FDA has approved revisions to the US prescribing information for ERBITUX (cetuximab). It is concerned with the treatment of patients

Cardax has reported that its lead compound Heptax has shown potential to address metabolic syndrome, including liver and cardiovascular disease as well as diabetes. Heptax is a bioavailable